Beam Therapeutics Inc.
BEAM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.55 | 0.22 | -0.29 | 0.83 |
| FCF Yield | -3.47% | -4.59% | -6.22% | -3.86% |
| EV / EBITDA | -18.71 | -16.62 | -11.85 | -22.77 |
| Quality | ||||
| ROIC | -11.11% | -9.77% | -8.91% | -10.70% |
| Gross Margin | 0.00% | 34.59% | 100.00% | -56.44% |
| Cash Conversion Ratio | 0.72 | 0.75 | 0.95 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -11.93% | -9.07% | -6.06% | 1.40% |
| Free Cash Flow Growth | -8.67% | 25.59% | -34.81% | 11.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 1.32 | 3.25 | 1.42 |
| Interest Coverage | -11.63 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -171.55 | 0.00 | 0.00 |